PRIM1
ENSG00000198056
Target class
Enzyme
Chromosome
12
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- PRIM1
- Gene name
- DNA primase subunit 1
- Gene symbol
- PRIM1
- Protein name
- DNA primase small subunit (EC 2.7.7.102) (DNA primase 49 kDa subunit) (p49)
- Gene biotype
- Protein coding
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 37.85
- Tissue specificity (Gini)
- 0.407
- Tissue specificity (tau)
- 0.873
- KEGG gene identifiers
- hsa:5557
- Protein interaction confidence
- 0.879814
- Protein interaction partners
- 59
- R-HSA-113501
- R-HSA-174411
- R-HSA-174430
- R-HSA-68952
- R-HSA-68962
- R-HSA-69091
- R-HSA-69166
- R-HSA-69183
- R-HSA-9710421
- End position
- 56752374
- Start position
- 56730438
- Chromosome
- 12
- Strand
- Reverse
- Tissue specificity (tau)
- 0.873453
- Expression inequality (Gini)
- 0.406523
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 37.85
- Testis
- 21.45
- Cells - Cultured fibroblasts
- 11.68
- Brain - Cerebellar Hemisphere
- 10.89
- Brain - Cerebellum
- 10.28
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes37.85
- Testis21.45
- Cells - Cultured fibroblasts11.68
- Brain - Cerebellar Hemisphere10.89
- Brain - Cerebellum10.28
- Ovary8.59
- Spleen8.26
- Cervix - Ectocervix7.57
- Uterus7.13
- Skin - Not Sun Exposed (Suprapubic)7.08
- Vagina6.78
- Skin - Sun Exposed (Lower leg)6.61
- Fallopian Tube6.57
- Nerve - Tibial6.46
- Cervix - Endocervix6.41
- Small Intestine - Terminal Ileum6.3
- Esophagus - Mucosa6.11
- Breast - Mammary Tissue5.64
- Adipose - Subcutaneous5.32
- Lung5.24
- Minor Salivary Gland5.22
- Bladder5
- Thyroid4.64
- Pituitary4.55
- Colon - Transverse4.34
And 29 more, listed on the interactive page.
- GO:0006269
- GO:0006270
- GO:0005654
- GO:0005658
- GO:0016020
- GO:0000287
- GO:0003899
- GO:0005515
- GO:0008270
- GO:0032553
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor